Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19
对一种用于治疗 COVID-19 的静脉注射冠状病毒 3CL 蛋白酶抑制剂进行临床前表征
期刊:Nature Communications
影响因子:14.7
doi:10.1038/s41467-021-26239-2
Britton Boras # ,Rhys M Jones # ,Brandon J Anson ,Dan Arenson ,Lisa Aschenbrenner ,Malina A Bakowski ,Nathan Beutler ,Joseph Binder ,Emily Chen ,Heather Eng ,Holly Hammond ,Jennifer Hammond ,Robert E Haupt ,Robert Hoffman ,Eugene P Kadar ,Rob Kania ,Emi Kimoto ,Melanie G Kirkpatrick ,Lorraine Lanyon ,Emma K Lendy ,Jonathan R Lillis ,James Logue ,Suman A Luthra ,Chunlong Ma ,Stephen W Mason ,Marisa E McGrath ,Stephen Noell ,R Scott Obach ,Matthew N O' Brien ,Rebecca O'Connor ,Kevin Ogilvie ,Dafydd Owen ,Martin Pettersson ,Matthew R Reese ,Thomas F Rogers ,Romel Rosales ,Michelle I Rossulek ,Jean G Sathish ,Norimitsu Shirai ,Claire Steppan ,Martyn Ticehurst ,Lawrence W Updyke ,Stuart Weston ,Yuao Zhu ,Kris M White ,Adolfo García-Sastre ,Jun Wang ,Arnab K Chatterjee ,Andrew D Mesecar ,Matthew B Frieman ,Annaliesa S Anderson ,Charlotte Allerton
